Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064376 · ClinicalTrials.gov registry record · Phase 2
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00064376 is a Phase 2 study that has completed, run by Cedars-Sinai Medical Center.
The verdict
NCT00064376, a Phase 2 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
Interventions
- DRUG paricalcitol
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064376
The ClinicalTrials.gov registry entry for NCT00064376 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paricalcitol is the first listed.
NCT00064376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064376 about?
NCT00064376 is a clinical study titled "Paricalcitol in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells. PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
What is the current status of trial NCT00064376?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-05. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00064376?
The interventions under investigation include: paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00064376?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.